BTIG Research Issues Pessimistic Forecast for Billiontoone (NASDAQ:BLLN) Stock Price

Billiontoone (NASDAQ:BLLN) had its target price lowered by research analysts at BTIG Research from $140.00 to $130.00 in a note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s target price suggests a potential upside of 39.85% from the stock’s previous close.

A number of other equities research analysts have also weighed in on BLLN. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Billiontoone in a report on Friday, May 1st. Wall Street Zen raised shares of Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Wells Fargo & Company lowered their price target on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Finally, Guggenheim lowered their price target on shares of Billiontoone from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, March 30th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Billiontoone presently has a consensus rating of “Moderate Buy” and an average price target of $122.43.

Billiontoone Stock Up 0.1%

BLLN opened at $92.96 on Thursday. The company has a current ratio of 10.92, a quick ratio of 11.32 and a debt-to-equity ratio of 0.18. Billiontoone has a 52-week low of $61.96 and a 52-week high of $138.70. The stock’s 50 day simple moving average is $77.96. The stock has a market capitalization of $4.27 billion and a P/E ratio of 442.67.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to analysts’ expectations of $95.81 million. Billiontoone’s quarterly revenue was up 83.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. Research analysts anticipate that Billiontoone will post 0.42 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Adams Street Partners LLC bought a new position in Billiontoone during the 4th quarter valued at $140,063,000. Baillie Gifford & Co. bought a new position in Billiontoone during the 4th quarter valued at $103,786,000. Price T Rowe Associates Inc. MD bought a new position in Billiontoone during the 4th quarter valued at $39,717,000. JPMorgan Chase & Co. bought a new position in Billiontoone during the 4th quarter valued at $32,078,000. Finally, Wasatch Advisors LP bought a new position in Billiontoone during the 1st quarter valued at $29,179,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.